Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaoyi Chong

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Journal of the Chinese Medical Association : JCMA|February 3, 2026
Construction and application of a genetically engineered mouse model of gastric adenocarcinomaYelizhati Madeti, Xiaoyi Chong, Xiaotian Zhang
Experimental and Therapeutic Medicine|February 20, 2018
Overexpression of microRNA-506-3p aggravates the injury of vascular endothelial cells in patients with hypertension by downregulating Beclin1 expressionFanfan Yi, Yugui Hao, Xiaoyi Chong, et al.
Human Cell|October 27, 2023
Tracking circulating PD-L1-positive cells to monitor the outcome of patients with gastric cancer receiving anti-HER2 plus anti-PD-1 therapyXiaoyi Chong, Yanyan Li, Jialin Lu, et al.
Aging|February 27, 2021
Integrative analysis of genomic, epigenomic and transcriptomic data identified molecular subtypes of esophageal carcinomaMingyang Ma, Yang Chen, Xiaoyi Chong, et al.
Cancers|September 9, 2022
Extracellular Vesicle-Derived Protein File from Peripheral Blood Predicts Immune-Related Adverse Events in Gastric Cancer Patients Receiving ImmunotherapyFangli Jiang, Zhening Zhang, Xiaoyi Chong, et al.
Discover Oncology|February 1, 2026
Association of clinicopathological characteristics and baseline peripheral blood lymphocyte subsets with efficacy of first-line immunotherapy in advanced gastric cancerWenfei Li, Sai Ge, Liyang Mo, et al.
American Journal of Cancer Research|November 17, 2025
Comparison of Alpha-fetoprotein-positive and AFP-negative patients with advanced gastroesophageal junction or gastric cancer receiving immunotherapy: an analysis stratified by HER2 statusHuizhen Liu, Wenfei Li, Jialin Lu, et al.
Journal of Extracellular Vesicles|April 1, 2022
Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancerCheng Zhang, Xiaoyi Chong, Fangli Jiang, et al.
Clinical and Translational Medicine|December 30, 2020
Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapiesCheng Zhang, Zuhua Chen, Xiaoyi Chong, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|March 8, 2024
Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective studyChangsong Qi, Xiaoyi Chong, Ting Zhou, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Journal of the Chinese Medical Association : JCMA|February 3, 2026
Construction and application of a genetically engineered mouse model of gastric adenocarcinomaYelizhati Madeti, Xiaoyi Chong, Xiaotian Zhang
Experimental and Therapeutic Medicine|February 20, 2018
Overexpression of microRNA-506-3p aggravates the injury of vascular endothelial cells in patients with hypertension by downregulating Beclin1 expressionFanfan Yi, Yugui Hao, Xiaoyi Chong, et al.
Human Cell|October 27, 2023
Tracking circulating PD-L1-positive cells to monitor the outcome of patients with gastric cancer receiving anti-HER2 plus anti-PD-1 therapyXiaoyi Chong, Yanyan Li, Jialin Lu, et al.
Aging|February 27, 2021
Integrative analysis of genomic, epigenomic and transcriptomic data identified molecular subtypes of esophageal carcinomaMingyang Ma, Yang Chen, Xiaoyi Chong, et al.
Cancers|September 9, 2022
Extracellular Vesicle-Derived Protein File from Peripheral Blood Predicts Immune-Related Adverse Events in Gastric Cancer Patients Receiving ImmunotherapyFangli Jiang, Zhening Zhang, Xiaoyi Chong, et al.
Discover Oncology|February 1, 2026
Association of clinicopathological characteristics and baseline peripheral blood lymphocyte subsets with efficacy of first-line immunotherapy in advanced gastric cancerWenfei Li, Sai Ge, Liyang Mo, et al.
American Journal of Cancer Research|November 17, 2025
Comparison of Alpha-fetoprotein-positive and AFP-negative patients with advanced gastroesophageal junction or gastric cancer receiving immunotherapy: an analysis stratified by HER2 statusHuizhen Liu, Wenfei Li, Jialin Lu, et al.
Journal of Extracellular Vesicles|April 1, 2022
Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancerCheng Zhang, Xiaoyi Chong, Fangli Jiang, et al.
Clinical and Translational Medicine|December 30, 2020
Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapiesCheng Zhang, Zuhua Chen, Xiaoyi Chong, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|March 8, 2024
Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective studyChangsong Qi, Xiaoyi Chong, Ting Zhou, et al.
Pageof 2